Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an extremely aggressive subtype associated with a poor prognosis. At present, the treatment for TNBC mainly relies on surgery and traditional chemotherapy. As a key component in the standard treatment of TNBC, paclitaxel (PTX) effectively inhibits the growth a...

Full description

Bibliographic Details
Main Authors: Longkun Wang, Chunqian Zhao, Lu Lu, Honglei Jiang, Fengshan Wang, Xinke Zhang
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:International Journal of Molecular Sciences
Subjects:
paclitaxel
peptide-drug conjugate
TAT peptide
A7R peptide
targeted delivery
anticancer therapy
Online Access:https://www.mdpi.com/1422-0067/24/5/4646

Similar Items

Similar Items